Monoclonal Antibodies against Platelet Membrane Glycoproteins IIb/IIIa and Ibα Inhibit Platelet Dependent Thrombin Generation by Different Mechanisms

Stephen Thomas; Paul Metcalfe; Alison H. Goodall; Elaine Gray

doi:10.1055/s-0037-1613975

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2000; 84(01): 98-103
DOI: 10.1055/s-0037-1613975

Commentary

Schattauer GmbH

Monoclonal Antibodies against Platelet Membrane Glycoproteins IIb/IIIa and Ibα Inhibit Platelet Dependent Thrombin Generation by Different Mechanisms

Stephen Thomas

²From the Division of Haematology, National Institute for Biological Standards and Control, Hertfordshire, UK

,

Paul Metcalfe

²From the Division of Haematology, National Institute for Biological Standards and Control, Hertfordshire, UK

,

Alison H. Goodall

¹Division of Chemical Pathology, University of Leicester, Leicester, UK

,

Elaine Gray

²From the Division of Haematology, National Institute for Biological Standards and Control, Hertfordshire, UK

› Author Affiliations

Abstract

Summary

The antithrombotic effect of antiplatelet agents is principally due to their anti-aggregatory action, but these agents may also interfere with coagulation. We have investigated the effect of monoclonal antibodies (MAb) to platelet membrane glycoproteins (GP) IIb/IIIa and Iba on thrombin generation.

Antibodies to platelet membrane glycoprotein IIb/IIIa (RFGP56 and c7E3) were shown to inhibit platelet-mediated thrombin generation stimulated by both intrinsic and extrinsic methods. An antibody to GP Ibα (RFGP37) also inhibited thrombin generation in these systems.

FITC-annexin V was used to determine the effect of these antibodies on the exposure of procoagulant phospholipids on the platelet membrane, and it was found that the anti-IIb/IIIa antibodies reduced this, whereas the anti-Ibα antibody caused an increase.

We conclude that our monoclonal antibodies against platelet membrane glycoproteins IIb/IIIa and Ibα inhibit platelet dependent thrombin generation by different mechanisms.

KeyWords

Platelets - glycoproteins - antibodies - thrombin generation

Full Text

References

References
1 Niewiarowski S. Secreted platelet proteins. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham E. eds. Edinburgh: Churchill Livingstone; 1994: 167-82.
2 Bevers EM, Comfurius P, van-Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-36.
3 Hemker HC, van-Rijn JL, Rosing J, van-Dieijen G, Bevers EM, Zwaal RF. Platelet membrane involvement in blood coagulation. Blood Cells 1983; 09: 303-17.
4 Califf RM, Lincoff AM, Tcheng JE, Topol EJ. An overview of the results of the EPIC trial. Eur Heart J 1995; 16 Suppl L: 43-9.
5 EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-61.
6 EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
7 CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-35.
8 Scrip. ReoPro plus thrombolysis looks more promising. Scrip 1998; 2324: 20.
9 Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
10 Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J Clin Invest 1996; 98: 863-74.
11 Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17: 528-35.
12 Herault JP, Peyrou P, Savi P, Bernat A, Herbert J. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb Haemost 1998; 79: 383-8.
13 Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res 1998; 90: 247-58.
14 Harmon JT, Jamieson GA. Platelet activation by thrombin in the absence of the high-affinity thrombin receptor. Biochemistry 1988; 27: 2151-7.
15 Harmon JT, Jamieson GA. The glycocalicin portion of platelet glycoprotein Ib expresses both high and moderate affinity receptor sites for thrombin. A soluble radioreceptor assay for the interaction of thrombin with platelets. J Biol Chem 1986; 261: 13224-9.
16 Dong JF, Sae TG, Lopez JA. Role of glycoprotein V in the formation of the platelet high-affinity thrombin-binding site. Blood 1997; 89: 4355-63.
17 Yamamoto N, Greco NJ, Barnard MR, Tanoue K, Yamazaki H, Jamieson GA, Michelson AD. Glycoprotein Ib (GPIb)-dependent and GPIb-independent pathways of thrombin-induced platelet activation. Blood 1991; 77: 1740-8.
18 Beguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999; 93: 564-70.
19 Cox AD. A study of platelet activation: the role of membrane glycoproteins of the integrin and selectin superfamilies. 1991 University of London. PhD Thesis..
20 Bye JM, Carter C, Cui Y, Gorick BD, Songsivilai S, Winter G, Hughes JN, Marks JD. Germline variable region gene segment derivation of human monoclonal anti-Rh(D) antibodies. Evidence for affinity maturation by somatic hypermutation and repertoire shift. J Clin Invest 1992; 90: 2481-90.
21 Gray E, Cesmeli S, Lormeau JC, Davies AB, Lane DA. Low affinity heparin is an antithrombotic agent. Thromb Haemost 1994; 71: 203-7.
22 Nurden AT, Nurden P. A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. Baillieres Clin Haematol 1993; 06: 653-90.
23 De-Marco L, Mazzucato M, Masotti A, Fenton JW, Ruggeri ZM. Function of glycoprotein Ib alpha in platelet activation induced by alpha-thrombin. J Biol Chem 1991; 266: 23776-83.
24 Saito H. The contact phase of blood coagulation. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham E. eds. Edinburgh: Churchill Livingstone; 1994: 289-308.
25 Isenberg WM, Bainton DF, Newman PJ. Monoclonal antibodies bound to subunits of the integrin GPIIb-IIIa are internalized and interfere with filopodia formation and platelet aggregation. Blood 1990; 76: 1564-71.
26 De-Marco L, Mazzucato M, Masotti A, Ruggeri ZM. Localization and characterization of an alpha-thrombin-binding site on platelet glycoprotein Ib alpha. J Biol Chem 1994; 269: 6478-84.
27 Byzova TV, Plow EF. Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation. J Biol Chem 1997; 272: 27183-8.
28 Santoso S, Zimmermann U, Neppert J, Mueller EC. Receptor patching and capping of platelet membranes induced by monoclonal antibodies. Blood 1986; 67: 343-9.
29 Yanabu M, Ozaki Y, Nomura S, Miyake T, Miyazaki Y, Kagawa H, Yamanaka Y, Asazuma N, Satoh K, Kume S, Komiyama Y, Fukuhara S. Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monoclonal antibody. Blood 1997; 89: 1590-8.